Antibodies toward high-density lipoprotein components inhibit paraoxonase activity in patients with systemic lupus erythematosus.

作者: J. R. BATUCA , P. R. J. AMES , D. A. ISENBERG , J. DELGADO ALVES

DOI: 10.1196/ANNALS.1422.016

关键词:

摘要: Patients with systemic lupus erythematosus (SLE) have an increased incidence of vascular disease, and oxidative stress is recognized as important feature in this condition, despite the underlying mechanisms not being fully understood. In these patients, interaction between lipoproteins immune system has been suggested, but most studies only looked at antibodies against oxidized low-density lipoproteins. This study was undertaken to determine presence directed high-density (HDL) identify a possible association paraoxonase (PON), antioxidant enzyme present HDL. Plasma from 55 patients SLE collected IgG aHDL antiapolipoprotein A-I (aApo A-I) were assessed by enzyme-linked immunosorbent assay. Standardization method performed control population 150 healthy subjects. levels above 5 standard deviations mean considered positive. PON activity quantification p-nitrophenol formation (micromol/mL/min). had higher titers (P < 0.0001) aApo antibodies, lower than controls. There also direct correlation (r = 0.61; P 0.0001). inversely correlated 0.0129) antibody levels. Anti-HDL high isolated subsequently incubated human These reduced up maximum 70.2% 78.4%, respectively. showed SLE. associated plasma, vitro inhibition assay confirmed activity.

参考文章(21)
M. Harangi, I. Seres, Z. Balogh, P. Kovács, G. Y. Paragh, G. Y. Kakuk, Gemfibrozil increases paraoxonase activity in type 2 diabetic patients. A new hypothesis of the beneficial action of fibrates Diabetes & Metabolism. ,vol. 27, pp. 604- 610 ,(2001)
Hitoshi Sakuraba, Norihiko Tonozuka, Norioki Tsuboi, Haruo Abe, Tohru Hayashi, Hirohumi Takanashi, Kouichirou Tahara, Shigeki Suzuki, Masato Umeda, Anti-apolipoprotein A-I autoantibody: characterization of monoclonal autoantibodies from patients with systemic lupus erythematosus. The Journal of Rheumatology. ,vol. 28, pp. 990- 995 ,(2001)
B N La Du, C M Wyte, H W Eckerson, The human serum paraoxonase/arylesterase polymorphism. American Journal of Human Genetics. ,vol. 35, pp. 1126- 1138 ,(1983)
Diana M. Shih, Lingjie Gu, Yu-Rong Xia, Mohamad Navab, Wan-Fen Li, Susan Hama, Lawrence W. Castellani, Clement E. Furlong, Lucio G. Costa, Alan M. Fogelman, Aldons J. Lusis, Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis Nature. ,vol. 394, pp. 284- 287 ,(1998) , 10.1038/28406
J. Delgado Alves, P. R. J. Ames, S. Donohue, L. Stanyer, J. Noorouz-Zadeh, C. Ravirajan, D. A. Isenberg, Antibodies to high-density lipoprotein and beta2-glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome. Arthritis & Rheumatism. ,vol. 46, pp. 2686- 2694 ,(2002) , 10.1002/ART.10542
A R Dinu, J T Merrill, C Shen, I V Antonov, B L Myones, R G Lahita, Frequency of antibodies to the cholesterol transport protein apolipoprotein A1 in patients with SLE. Lupus. ,vol. 7, pp. 355- 360 ,(1998) , 10.1191/096120398678920262
Nevila Hyka, Jean-Michel Dayer, Christine Modoux, Tadahiko Kohno, Carl K. Edwards, Pascale Roux-Lombard, Danielle Burger, Apolipoprotein A-I inhibits the production of interleukin-1β and tumor necrosis factor-α by blocking contact-mediated activation of monocytes by T lymphocytes Blood. ,vol. 97, pp. 2381- 2389 ,(2001) , 10.1182/BLOOD.V97.8.2381
O. Vaarala, K. Aho, T. Palosuo, G. Alfthan, M. Jauhiainen, M. Leirisalo-Repo, Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus The Lancet. ,vol. 341, pp. 923- 925 ,(1993) , 10.1016/0140-6736(93)91213-6